Hims & Hers to Launch Wegovy Copy at $49 Intro, Faces Novo Nordisk Legal Threats

Telehealth compounding firm Hims & Hers announced February 5, 2026, it will launch an off-label, compounded copy of Wegovy at $49 for the first month, followed by $99, leveraging high demand for GLP-1 weight-loss therapies. The move follows Novo Nordisk’s reformulated semaglutide pill and comes after the FDA issued a September 2025 warning letter over misleading marketing. Novo Nordisk immediately issued a statement vowing legal and regulatory action, citing the product as unapproved, inauthentic, and untested, and warned it would protect intellectual property and the integrity of the U.S. drug approval framework. The FDA permits compounding for personalized dosages, but Hims’ offering faces renewed scrutiny as the agency works to phase out compounding for off-label drugs. Novo Nordisk A/S shares fell more than 5% in afternoon trading on the news.